Gold prices steady amid Fed rate cut hopes; Trump-Putin talks awaited
On Friday, Piper Sandler analysts reiterated their Overweight rating for BridgeBio Pharma (NASDAQ:BBIO) stock, maintaining a price target of $63.00. The stock has shown remarkable momentum, gaining nearly 12% in the past week and trading close to its 52-week high of $39.54. According to InvestingPro data, analyst targets range from $41 to $95, reflecting strong market confidence in the company’s potential. The analysts highlighted the upcoming Phase 3 topline readout of the CALIBRATE study for encaleret, a calcilytic drug developed by BridgeBio Pharma. The study’s results are expected to be released in the second half of 2025, particularly around September or October. With a market capitalization of $7.27 billion and a strong current ratio of 4.57, InvestingPro analysis indicates the company has sufficient liquidity to support its clinical development programs.
The analysts noted that the positive efficacy data from the Phase 2b study of encaleret in patients with autosomal dominant hypocalcemia type 1 (ADH1) support a favorable outcome for the CALIBRATE study, which involves 67 patients with ADH1. They estimated risk-adjusted peak sales for ADH1 in the US and EU markets to reach $389 million, accounting for a 40% discount. This figure represents approximately 9% of BridgeBio Pharma’s total product revenues.
In addition to the ADH1 indication, the analysts pointed out potential implications for a broader chronic hypoparathyroidism indication. They suggested that the CALIBRATE study might help reduce risks associated with expanding encaleret’s use to this broader condition, given its biochemical and background medical perspectives.
The reiteration of the Overweight rating and price target reflects Piper Sandler’s confidence in BridgeBio Pharma’s ongoing developments and the potential market impact of encaleret, pending successful study outcomes. With projected revenue growth of 85% for FY2025, the company shows promising financial trajectory. For deeper insights into BridgeBio’s valuation and growth prospects, investors can access comprehensive analysis through InvestingPro’s detailed research reports, which provide expert analysis on over 1,400 US stocks.
In other recent news, BridgeBio Pharma reported strong financial results for the first quarter of 2025, with total revenues reaching $116.6 million. This growth was primarily driven by the successful launch of their drug, Attruby, which generated $36.7 million in net revenue. Scotiabank (TSX:BNS) has responded to this performance by raising its price target for BridgeBio to $55, citing the strong sales of Attruby. Additionally, BMO Capital increased its price target for the company to $42, reflecting updated expectations for future sales performance.
BridgeBio Pharma has also announced significant findings from their ATTRibute-CM Phase 3 trial, demonstrating that their drug acoramidis is associated with improved survival rates in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The U.S. FDA has approved acoramidis under the brand name Attruby, with approvals also secured in Europe, Japan, and the UK. Furthermore, BridgeBio has initiated the ACT-EARLY clinical trial, dosing the first asymptomatic participant to test acoramidis as a preventative treatment for transthyretin amyloid disease (ATTR).
The company’s strategic focus on patient access and support has enhanced its competitive position in the ATTR Cardiomyopathy market, which is expected to grow significantly. BridgeBio’s recent developments indicate a promising trajectory, with analysts from firms like BMO Capital and Scotiabank expressing optimism about the company’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.